These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24957419)

  • 1. Managed entry agreements for pharmaceuticals in Australia.
    Vitry A; Roughead E
    Health Policy; 2014 Sep; 117(3):345-52. PubMed ID: 24957419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Australian managed entry scheme: a new manageable process for the reimbursement of new medicines?
    Wonder M; Backhouse ME; Sullivan SD
    Value Health; 2012 May; 15(3):586-90. PubMed ID: 22583471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
    Robinson MF; Mihalopoulos C; Merlin T; Roughead E
    Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
    Robertson J; Walkom EJ; Henry DA
    Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
    Maskineh C; Nasser SC
    Value Health Reg Issues; 2018 Sep; 16():33-38. PubMed ID: 29936067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.
    Ferrario A; Kanavos P
    Soc Sci Med; 2015 Jan; 124():39-47. PubMed ID: 25461860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
    Kingham R; Wheeler J
    Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.
    Efthymiadou O; Kanavos P
    BMC Health Serv Res; 2022 Aug; 22(1):1066. PubMed ID: 35987627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
    Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
    Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
    Persson U; Willis M; Odegaard K
    Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
    Lipworth W; Doran E; Kerridge I; Day R
    Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.